Table 3

Social capital and HIV-antiretroviral adherence among people living with HIV
Site N Social Capital μ (sd) Adherence % past 30-day μ (sd) Adherence 100%a n (%) Prescribed HIV antiretroviral therapy n (%)
Canada 100 2.54 (0.56) 84.1 (24.7) 37 (43.5) 85 (85)
Puerto Rico 100 2.74 (0.52) 88.7 (20.1) 51 (56) 91 (91)
California 300 2.53 (0.59) 82.7 (23.2) 86 (36.8) 234 (78)
Hawaii 100 2.73 (0.56) 89.6 (14) 32 (35.2) 91(91)
Illinois 95 2.66 (0.59) 83.4 (24.4) 29 (36.3) 80 (84)
Massachusetts 200 2.67 (0.54) 84.8 (23.2) 70 (40.7) 172 (86)
New Jersey 100 2.64 (0.48) 85.1 (21.9) 36 (43.4) 83 (83)
New York 100 2.69 (0.59) 83 (23.7) 31 (37.8) 82 (82)
North Carolina 200 2.79 (0.55) 86.1 (19.7) 78 (43.3) 180 (90)
Ohio 150 2.59 (0.52) 86.1 (20.9) 53 (41.4) 128 (85)
Texas 228 2.64 (0.52) 89.5 (19) 109 (55.6) 196 (86)
Washington 200 2.54 (0.56) 85.8 (23.8) 87 (51.8) 168 (84)
Total 1,873 2.63 (0.55) 85.7 (21.8) 699 (44) 1,590 (84.9)

Note. a = computed from 30-day adherence data; possible mean social capital scores range from 1 indicating poor social capital to 4 indicating high social capital.

Phillips et al.

Phillips et al. BMC Public Health 2013 13:736   doi:10.1186/1471-2458-13-736

Open Data